Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer

Alissandra L Hillis; Alex Toker

doi:10.1016/j.ccell.2020.09.011

Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer

Cancer Cell. 2020 Oct 12;38(4):441-443. doi: 10.1016/j.ccell.2020.09.011.

Authors

Alissandra L Hillis¹, Alex Toker²

Affiliations

¹ Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. Electronic address: alhillis@g.harvard.edu.
² Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. Electronic address: atoker@bidmc.harvard.edu.

PMID: 33049205
DOI: 10.1016/j.ccell.2020.09.011

Abstract

Predictive biomarkers can facilitate optimal patient selection for targeted cancer therapies. In this issue of Cancer Cell, Ros et al. show the utility of noninvasive metabolic imaging of labeled carbon transfer from pyruvate to lactate to detect early response and FOXM1-mediated resistance to PI3K inhibition in estrogen-receptor-positive breast cancer.

Publication types

Comment

MeSH terms

Breast Neoplasms* / drug therapy
Forkhead Box Protein M1
Humans
Lactic Acid
Phosphatidylinositol 3-Kinases / genetics
Protein Kinase Inhibitors / pharmacology

Substances

FOXM1 protein, human
Forkhead Box Protein M1
Protein Kinase Inhibitors
Lactic Acid